Assessing the Safety and Tolerability of NMN in DHDDS-CDG

Conditions

• Congenital Disorder of Glycosylation
• DHDDS-CDG
• DHDDS-Congenital Disorder of Glycosylation

Eligibility Criteria

Sex

ALL

Age

4 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Nicotinamide Mononucleotide (NMN) Nucleosidase — DRUG
  Name: nicotinamide mononucleotide (NMN) Form: measured powder Dose: 250 mg/day Frequency: Daily Route of administration: Oral

Study Details

The primary objective of this study is to evaluate the safety and tolerability of the dietary supplement, nicotinamide mononucleotide (NMN), in individuals with dehydrodolichol diphosphate synthase congenital disorder of glycosylation (DHDDS-CDG). This will to contribute to knowledge that will allow healthcare providers to make informed decisions about recommending this dietary supplement in this population.

Key Dates

First listed

May 7, 2026

Start date

May 8, 2026

Status verified

Jun 2026

Primary completion

Aug 1, 2027

Completion

Aug 1, 2027

Study Design

Enrollment

8 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: nicotinamide mononucleotide (NMN)
  Participants will take 250mg NMN daily.

Primary Outcome Measure

Incidence of adverse events (AEs) [ Time Frame: up to 12 months ]

Central Contacts

• Georgia MacDonald, MS, CGC
  646-946-6923
  [email protected]

Locations (1)

Find similar trials in New York, NY